Get started
Author

Kritiya Butthongkomvong

Observed name: Butthongkomvong,Kritiya
ORCID: 0000-0003-3714-7113
Observed ORCID: 0000-0003-3714-7113
OpenAlex ID: A5013508821
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 · Robin Kate Kelley, Makoto Ueno, et al. · The Lancet · 1,310
Treatment Outcome of Palliative Chemotherapy in Inoperable Cholangiocarcinoma in Thailand
2013 · Kritiya Butthongkomvong, Ekaphop Sirachainan, et al. · Asian Pacific Journal of Cancer Prevention · 24
PDF
Expression and Serum Levels of Mucin 5AC (MUC5AC) as a Biomarker for Cholangiocarcinoma: a Meta-analysis
2017 · Noel Pabalan, Sutawadee Sukcharoensin, et al. · Journal of Gastrointestinal Cancer · 18
Update on the risk factors for opisthorchiasis and cholangiocarcinoma in Thailand
2023 · Sattrachai Prasopdee, Thittinan Rojthongpond, et al. · Parasites Hosts and Diseases · 14
PDF
microRNA profiling of exosomes derived from plasma and their potential as biomarkers for Opisthorchis viverrini-associated cholangiocarcinoma
2024 · Kittiya Supradit, Kanokpan Wongprasert, et al. · Acta Tropica · 11
BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase
2014 · Steen Lindkær-Jensen, Stig Larsen, et al. · Breast Cancer Targets and Therapy · 11
PDF
Differential plasma proteomes of the patients with Opisthorchiasis viverrini and cholangiocarcinoma identify a polymeric immunoglobulin receptor as a potential biomarker
2022 · Sattrachai Prasopdee, Yodying Yingchutrakul, et al. · Heliyon · 9
PDF
Differential circulating miRNA profiles identified miR-423-5p, miR-93-5p, and miR-4532 as potential biomarkers for cholangiocarcinoma diagnosis
2024 · Kittiya Supradit, Sattrachai Prasopdee, et al. · PeerJ · 8
PDF
Investigation of Plasma Cell-Free DNA and MiRNA in Cholangiocarcinoma and Opisthorchiasis Viverrini Patients
2024 · Sattrachai Prasopdee, Montinee Pholhelm, et al. · Asian Pacific Journal of Cancer Prevention · 8
PDF
Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study
2019 · Kritiya Butthongkomvong, Nilubol Raunroadroong, et al. · Breast Cancer Targets and Therapy · 7
PDF
Biomarker potential of plasma cell-free DNA for cholangiocarcinoma
2024 · Sattrachai Prasopdee, Sissades Tongsima, et al. · Heliyon · 4
PDF
Economic evaluation of a robotic chemotherapy compounding system and its service expansion to network hospital in Thailand
2025 · Araya Lukanawonakul, Somchai Thanasitthichai, et al. · BMC Health Services Research · 3
PDF
Efficacy and safety of Thai herbal recipe in advanced hepatocellular carcinoma: A pilot, randomized, controlled clinical trial
2019 · Kritiya Butthongkomvong, Araya Lukanawonakul, et al. · Advancement in Medicinal Plant Research · 1
PDF
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
2026 · Makoto Ueno, Changhoon Yoo, et al. · EClinicalMedicine
miR-1294 Upregulation as a Diagnostic Biomarker for Cholangiocarcinoma
2026 · Kittiya Supradit, Teva Phanaksri, et al. · Asian Pacific Journal of Cancer Prevention
PDF
Plasma S100A9 Levels in Healthy Individuals, Opisthorchis viverrini-Infected Individuals, and Patients with Cholangiocarcinoma
2026 · Piyaluk Danchaivijitr, Montinee Pholhelm, et al. · Asian Pacific Journal of Cancer Prevention
PDF
Polymeric Immunoglobulin Receptor-Lateral Flow Immunochromatographic Strip for Cholangiocarcinoma Screening
2026 · Umaporn Pimpitak, Sattrachai Prasopdee, et al. · Archives of Medical Research
BP-C1 in treatment of pretreated metastatic breast cancer: A meta-analysis of two randomized, double-blind and placebo-controlled multicenter studies.
2019 · Stig Einride Larsen, Kritiya Butthongkomvong, et al. · Journal of Global Oncology
Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study
2019 · Butthongkomvong,Kritiya, Raunroadroong,Nilubol, et al. · Dove Medical Press (Taylor and Francis Group)
Correlation Between Cytidine Deaminase Polymorphism and Gemcitabine in Efficacy and Toxicity
2018 · Suda Vannaprasaht, Duanggamon Muengsaen, et al. · Proceedings for Annual Meeting of The Japanese Pharmacological Society
PDF
Do the efficacy of BP-C1 correlate to receptor status in patients suffering from metastatic breast cancer stage IV?
2017 · Stig Einride Larsen, Kritiya Butthongkomvong, et al. · Journal of Clinical Oncology
The Effect of CytidineDeaminase Polymorphisms on Hematotoxicity in Thai Cancer Patients Treated with Gemcitabine-based Chemotherapy
2016 · Duanggamon Muengsaen, Suda Vannaprasaht, et al. · ศรีนครินทร์เวชสาร (Srinagarind Medical Journal)
BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum]
2015 · Steen Lindkær-Jensen, Stig Larsen, et al. · Breast Cancer Targets and Therapy
PDF
Works count: 24
Citation count: 1,428
H-index: 8
I10-index: 6
Year
Topic
Type